Allogene Therapeutics Inc (NASDAQ: ALLO) kicked off on Tuesday, up 6.50% from the previous trading day, before settling in for the closing price of $1.23. Over the past 52 weeks, ALLO has traded in a range of $0.86-$3.78.
During the last 5-year period, the sales growth of Healthcare Sector giant was 6.26%. While this was happening, its average annual earnings per share was recorded 29.47%. With a float of $156.53 million, this company’s outstanding shares have now reached $223.16 million.
Allogene Therapeutics Inc (ALLO) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Allogene Therapeutics Inc is 30.35%, while institutional ownership is 50.56%. The most recent insider transaction that took place on Nov 17 ’25, was worth 959. Before that another transaction happened on Oct 21 ’25, when Company’s CHIEF FINANCIAL OFFICER sold 36,744 for $1.26, making the entire transaction worth $46,169. This insider now owns 1,276,796 shares in total.
Allogene Therapeutics Inc (ALLO) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.28 earnings per share (EPS), higher than consensus estimate (set at -0.32) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 29.47% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.23% during the next five years compared to 6.26% growth over the previous five years of trading.
Allogene Therapeutics Inc (NASDAQ: ALLO) Trading Performance Indicators
Take a look at Allogene Therapeutics Inc’s (ALLO) current performance indicators. Last quarter, stock had a quick ratio of 8.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.98, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.88 in one year’s time.
Technical Analysis of Allogene Therapeutics Inc (ALLO)
Looking closely at Allogene Therapeutics Inc (NASDAQ: ALLO), its last 5-days average volume was 2.41 million, which is a drop from its year-to-date volume of 3.98 million. As of the previous 9 days, the stock’s Stochastic %D was 87.26%.
During the past 100 days, Allogene Therapeutics Inc’s (ALLO) raw stochastic average was set at 46.16%, which indicates a significant decrease from 100.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0814 in the past 14 days, which was lower than the 0.0866 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2284, while its 200-day Moving Average is $1.3705. However, in the short run, Allogene Therapeutics Inc’s stock first resistance to watch stands at $1.3400. Second resistance stands at $1.3700. The third major resistance level sits at $1.4300. If the price goes on to break the first support level at $1.2500, it is likely to go to the next support level at $1.1900. Now, if the price goes above the second support level, the third support stands at $1.1600.
Allogene Therapeutics Inc (NASDAQ: ALLO) Key Stats
The company with the Market Capitalisation of 294.40 million has total of 224,730K Shares Outstanding. Its annual sales at the moment are 20 K in contrast with the sum of -257,590 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -41,400 K.
